Celldex Therapeutics (CLDX) EBITDA Margin (2010 - 2026)
Celldex Therapeutics' EBITDA Margin was -362368.18% in Q2 2026, down 353740.24 percentage points from -8627.95% a year earlier but up 194838.48 percentage points from the prior quarter.
Celldex Therapeutics (CLDX) EBITDA Margin (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Celldex Therapeutics' EBITDA Margin was -204070.89% through Jun 30, 2026, down 200074.96 percentage points year-over-year; for FY2025, it came in at -18381.04%, down 15647.40 percentage points from FY2024.
- EBITDA Margin shows a five-year change of -17579.94 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was -2733.63% in FY2024 (-532.06 pp), -2201.57% in FY2023 (+2564.57 pp), -4766.14% in FY2022 (-3300.33 pp) and -1465.81% in FY2021 (-664.72 pp).
- Quarterly EBITDA Margin has moved between -557206.67% (Q1 2026) and -1134.54% (Q4 2023) over five years.
- Compared with a year earlier, EBITDA Margin has declined for three straight quarters, with an average year-over-year change of -137339.71 percentage points over the last seven quarters.
- The best year-over-year quarter for EBITDA Margin over five years was Q1 2025 (a gain of 16631.53 percentage points); the worst was Q1 2026 (a drop of 548304.22 percentage points).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Celldex Therapeutics | 2.47 Bn | 2.47 Bn | - | -362,368.18% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -362,368.18% |
| Mar 31, 2026 | -557,206.67% |
| Dec 31, 2025 | -71,352.89% |
| Jun 30, 2025 | -8,627.95% |
| Mar 31, 2025 | -8,902.45% |
| Dec 31, 2024 | -4,698.55% |
| Sep 30, 2024 | -1,608.90% |
| Jun 30, 2024 | -1,822.26% |
| Mar 31, 2024 | -25,533.97% |
| Dec 31, 2023 | -1,134.54% |
| Sep 30, 2023 | -2,667.90% |
| Jun 30, 2023 | -12,107.84% |
| Mar 31, 2023 | -3,282.83% |
| Dec 31, 2022 | -1,687.04% |
| Sep 30, 2022 | -6,640.05% |
| Jun 30, 2022 | -21,874.23% |
| Mar 31, 2022 | -12,900.00% |
| Dec 31, 2021 | -5,857.19% |
| Sep 30, 2021 | -13,118.95% |
| Jun 30, 2021 | -364.25% |
Celldex Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CLDX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CLDX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CLDX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();